Skip to main content

Guidance in the ages of neuroscience

Over the past two decades important progress has been made in the area of intervention in psychiatric disorders, mainly with the introduction of novel antidepressant and antipsychotic drugs. Despite these advances, the interindividual differences in the psychotropic drug response and the development of drug-induced adverse effects remain a serious problem in clinical practice. On the other hand, more information about the mechanisms of action of psychotropic drugs may help the way they should be prescribed. In this regard application of technological advances in the field of neurosciences, namely modern neuroimaging methods and the enormously developed molecular genetics acquires paramount importance. PET and SPECT studies have indicated that antipsychotic response is associated with blockade of dopamine D2 receptors and antidepressant response has been linked to blockade of serotonin transporter receptors. According to Zipurski et al (2007), these findings have the following clinical implications: a) antipsychotic dosing for most patients with schizophrenia can be expected to occur within a narrow range of D2 receptor blockade, (b) Antidepressant response for must patients can be expected to occur with blockade of 80% or more of the serotonin transporter. Pharmacogenetics and pharmacogenomics signal the beginning of a new era in the treatment psychiatric disorders. They provide a novel method in the search of informative correlates of psychotropic drug response. Polymorphisms of dopamine and serotonin receptor subtypes, transporter proteins and metabolic enzymes may contribute to variability in response to psychotropic drugs and the occurrence of their adverse reactions. In the field of molecular biology, it has been demonstrated that psychotropic drugs used to treat mood disorders, target molecules and signaling cascades implicated in the control of neuroplasticity. Our expanding knowledge of psychopharmacology will help lead to specific targeting for more predictable and safer medications in the near future. It is believed that perspectives are outstanding to achieve benefits previously unattainable.

References

  1. 1.

    Bolonna AA, Arranz MJ, Mancama D, Kerwin RW: Pharmacogenomics - can genetics keep in the care of psychiatric patients?. Intern Rev Psychiatry. 2004, 16: 311-319. 10.1080/09540260400014369.

    CAS  Article  Google Scholar 

  2. 2.

    Schloesser RJ, Huang J, Klein PS, Manji HK: Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorders. Neuropsychopharmacology Rev. 2008, 33: 110-133. 10.1038/sj.npp.1301575.

    CAS  Article  Google Scholar 

  3. 3.

    Zipurski RB, Meyer JH, Verhoeff NP: PET and SPECT imaging in psychiatric disorders. Can J Psychiatry. 2007, 52: 146-157.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Lefteris Lykouras.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Lykouras, L. Guidance in the ages of neuroscience. Ann Gen Psychiatry 9, S45 (2010). https://doi.org/10.1186/1744-859X-9-S1-S45

Download citation

Keywords

  • Dopamine
  • Schizophrenia
  • Mood Disorder
  • Antipsychotic Drug
  • Psychotropic Drug